The invention relates to a catalyst which comprises: a) a mixed metal oxide of molybdenum, vanadium, niobium and optionally tellurium; and b) ceria particles having a crystallite size greater than 15 nanometers (nm); wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Further, the invention relates to a process for preparing a catalyst, which comprises mixing a mixed metal oxide of molybdenum, vanadium, niobium and optionally tellurium with ceria particles having a crystallite size greater than 15 nanometers (nm), wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Still further, the invention relates to an alkane oxidative dehydrogenation and/or alkene oxidation process wherein such catalyst is used.

The invention relates to a catalyst which comprises: a) a mixed metal oxide of molybdenum, vanadium, niobium and optionally tellurium; and b) ceria particles having a crystallite size greater than 15 nanometers (nm); wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Further, the invention relates to a process for preparing a catalyst, which comprises mixing a mixed metal oxide of molybdenum, vanadium, niobium and optionally tellurium with ceria particles having a crystallite size greater than 15 nanometers (nm), wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Still further, the invention relates to an alkane oxidative dehydrogenation and/or alkene oxidation process wherein such catalyst is used.

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions. ##STR00001##

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions. ##STR00001##

Disclosed is a method for synthesis of fatty acids by culturing a eukaryotic microorganism from the fungi kingdom, that is naturally oleaginous or rendered oleaginous. The culture is performed in the presence a fatty acid synthase inhibitor in the culture medium.

The present invention relates to a process for carbonylating allyl alcohols at low temperature, low pressure and/or low catalyst loading. In an alternative embodiment, an acylation product of the allyl alcohol is used for the carbonylation. The present invention likewise relates to the preparation of conversion products of these carbonylation products and specifically of (−)-ambrox.

The present invention relates to a process for carbonylating allyl alcohols at low temperature, low pressure and/or low catalyst loading. In an alternative embodiment, an acylation product of the allyl alcohol is used for the carbonylation. The present invention likewise relates to the preparation of conversion products of these carbonylation products and specifically of (−)-ambrox.

The invention relates to a catalyst which comprises: a) a mixed metal oxide of molybdenum, vanadium, niobium and in optionally tellurium; and b) ceria particles having a crystallite size greater than 15 nanometers (nm); wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Further, the invention relates to a process for preparing a catalyst, which comprises mixing a mixed metal oxide of molybdenum, vanadium, niobium and optionally tellurium with ceria particles having a crystallite size greater than 15 nanometers (nm), wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Still further, the invention relates to an alkane oxidative dehydrogenation and/or alkene oxidation process wherein such catalyst is used.

The invention relates to a catalyst which comprises: a) a mixed metal oxide of molybdenum, vanadium, niobium and in optionally tellurium; and b) ceria particles having a crystallite size greater than 15 nanometers (nm); wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Further, the invention relates to a process for preparing a catalyst, which comprises mixing a mixed metal oxide of molybdenum, vanadium, niobium and optionally tellurium with ceria particles having a crystallite size greater than 15 nanometers (nm), wherein the amount of the ceria particles, based on the total amount of the catalyst, is of from 1 to 60 wt. %. Still further, the invention relates to an alkane oxidative dehydrogenation and/or alkene oxidation process wherein such catalyst is used.

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.

##STR00001##